Making the DARPin Difference Reality for Patients

Transcription

1 Making the DARPin Difference Reality for Patients Corporate Presentation of Molecular Partners AG, Switzerland (SIX: MOLN) June 4, Molecular Partners AG Slide 1

2 Molecular Partners: Who We Are $ Teamwork Swiss biotech (SIX: MOLN) 12 team members Discovery to Phase 2 (POC) Science & patients first DARPin Therapies Abicipar in Phase 3 (ophtha) MP25 in Phase 2 (onc) MP274 in Phase 1 (onc) Broad preclin. I/O portfolio Partnerships Alliance with Allergan Collaboration with AstraZeneca Cash CHF 13mn (Q1 218) Financed well beyond key value inflection points DARPin Platform DARPin Difference: unlock novel modes of action Proof of Platform in the eye and systemically Fast and cost effective drug discovery engine 218 Molecular Partners AG Slide 2

3 Technology Platform A Differentiated Platform to Fill the Pipeline DARPin Difference Identify unique product candidate Patient Need Define target(s) Screen for desired phenotype Apoptosis Activation via clustering etc. Mono-DARPin library (>1 12 ) Build multi-darpin library (>1, multi-darpin combinations) Select highly diverse mono-darpin proteins to various epitopes 218 Molecular Partners AG Slide 3

4 Technology Platform DARPin Proteins: A Different Class of Therapeutics Derived from ankyrin repeat proteins which are naturally occurring binding proteins in multifunctional contexts Drug discovery engine Mono-specific DARPin proteins are selected to a target from large DARPin libraries Fast and cost-effective process High affinity target binding Flexible architecture Mono-DARPin Multi-DARPin MP25: Combination therapy in one DARPin Difference Collections of 1, multi-darpin candidates are screened for MoA Ideal properties Small size, high affinity, high stability, high developability as mono & multi-darpin proteins Multi-DARPin candidates: Linked mono-darpin domains ( 6 so far) Form to function: Different linkers short, long, flexible, rigid depending on the target biology MP274: handcuff MP31: Tumor-localized Switch 218 Molecular Partners AG Slide 4 Proof of platform Low immunogenicity of multi-darpin proteins and long t 1/2 in bloodstream (14 days) and eye Adjustable exposure

5 DARPin Engine: Unlimited Source of Candidates I/O Ophthalmology Oncology Pipeline Balanced and Robust Portfolio Discovery Preclinical Phase 1 Phase 2 Phase 3 MP25 in MM MP25 in EGFR-mut NSCLC* MP274: HER2+ patients MP31: 4-1BB-FAP multi-darpin Multiple discovery programs Abicipar in wet AMD Abicipar in DME Three DARPin candidates Partnership Additional discovery programs AMD, age-related macular degeneration; DME, diabetic macular edema; MM, multiple myeloma; NSCLC, non-small cell lung cancer. *Collaboration with AstraZeneca for Tagrisso supply 218 Molecular Partners AG Slide 5

6 Pipeline Turning the DARPin Differentiation into Patient Outcome Our Target Profiles Preclinical Phase 1 Phase 2 Phase 3 MP31 MP274 MP25 Abicipar NSCLC Wet AMD MM Tumor-restricted activity (switch) to avoid doselimiting side effects Molecular handcuff inducing cell death in HER2+ cancer cells Blocking 2 key escape pathways in parallel Long-acting VEGF inhibitor in the eye Opening a new therapeutic window for combinations Activity in patients no longer benefiting from approved antibodies Restore activity of drugs to which cancer has become resistant in MM and NSCLC Noninferiority to competition with less frequent ocular injections 218 Molecular Partners AG Slide 6

7 Value Pipeline Ready to Capture Value Beyond Ophthalmology Oncology Value in our proprietary oncology pipeline Ophthalmology Value in ophthalmology with our partner Allergan Time 218 Molecular Partners AG Slide 7

8 Oncology MP25: A First-in-Class Bi-Specific DARPin Molecule MP25 First bi-specific biologic blocking VEGF and HGF VEGF and HGF/c-MET key escape pathways for several SOC treatments Escape described for hematologic malignancies and solid tumors Blocking these escape pathways may restore activity of SOC drugs Our choice of indications Multiple myeloma (MM) EGFR-mutated non-small cell lung cancer (NSCLC) Potential in additional indications and combinations HGF DARPin VEGF DARPin HSA DARPin Fully owned by Molecular Partners IP protection at least until 236 SOC, standard of care; HSA, human serum albumin. 218 Molecular Partners AG Slide 8

9 Oncology MP25 Blocks Two Tumor Escape Pathways Untreated Upregulation of escape pathways after SOC MP25 Medical Need: agents that block escape pathways to SOC VEGF VEGF VEGF Tumor pathways HGF (c-met) SOC HGF (c-met) HGF (c-met) HSA MP Molecular Partners AG Slide 9

10 Tumor Volume (mm 3 ) Combined HGF and VEGF Inhibition Leads to Synergistic Effect in Mouse Model 2 5 Oncology Tumor Growth Inhibition Syngeneic colorectal cancer model* (MC38) MP Vehicle Anti-HGF Anti-VEGF Anti-VEGF & Anti-HGF MP Treatment (days) *Syngeneic model: HGF c-met axis fully functional murine tumor grown in mouse strain of origin. 218 Molecular Partners AG Slide 1

11 Relative Tumor Volume (%) Oncology MP25 can be Combined with Many Agents Across Different Tumors to Increase Their Efficacy MP25 Gastric cancer PDX model GXA327 Head & neck cancer PDX model HNXF195 Pancreatic cancer tumor model KP4 8 V e h ic le 1 V e h ic le 2 5 V e h ic le M P 2 5 M P 2 5 M P P a c lita x e l M P p a c lita x e l 8 C is p la tin M P c is p la tin 2 G e m c ita b in e M P g e m c ita b in e PDX model, patient-derived xenograft mouse model Treatment (days) Molecular Partners AG Slide 11

12 Oncology MP25 in Phase 1: Safe, Convenient Dosing Clear Signs of Efficacy even on stand-alone base MP25 Dosing* Convenient, flexible administration Exposure Repeated Favorable dosing exposure resulted in good exposure Safety Well tolerated Efficacy Clear signs of antitumor even stand-alone efficacy Infusion Well tolerated well tolerated Dosing 2 / 3 weekly every 2 or 3 weeks possible Half-life ~2 weeks Systemic half-life: Convenient 1 hr infusion ~2 weeks Sustained drug exposure throughout over multiple treatment cycles (up periods to 1 yr) (max. to date >12 months) Low immunogenicity Only (only 1/41 out patients of 4 developed patients with a relevant titer increase of ADAs in ADA (>1 titres) fold above background) Most common AE: was hypertension, generally well controlled with AEs as expected for standard medication: any VEGF inhibitor AEs were as expected for a VEGF inhibitor 2 Significant patients showed reduction in significant tumor volume reduction in two in tumor patients volume Treatment duration was 3 (% mo of patients): in 18 patients (4%) 3 months and 6 for mo 4% in 4 6 patients months (1%) for 1% First-in-human data strongly encourage development of DARPin therapy via systemic administration 218 Molecular Partners AG Slide 12

13 Biological rationale Oncology Initial Indications Selected for Phase 2: MM and NSCLC multiple indications on radar Multiple myeloma MP25 Head & neck squamous-cell EGFR-mutated NSCLC Nasopharyngeal HCC Colorectal cancer Anal cancer Feasibility of internal clinical development* Bubble size indicates estimated relative market potential (incidences). Source: Datamonitor. *Based on internal assessment on speed to market and complexity of development program. Potential of gastric, renal and other cancers under evaluation. 218 Molecular Partners AG Slide 13

14 p-c-met Oncology p-c-met Resistance in MM: up-regulation of HGF & VEGF mabs HGF Resistance to SOC VEGF Bone Marrow HGF score 3+ Patients 6/8 Newly diagnosed VEGF On partial remission HGF&VEGF Resistant HGF Relapsed 2+ 2/8 28% 2% 92% 89% 1+ /8 4% 3% 7% c-met c-met c-met c-met Moschetta M, et al. Clin Cancer Res 213;19: ; 2. White D, et al. Cancer 213;119: Molecular Partners AG Slide 14

15 Oncology MP25 Unique Approach in MM Break Resistance & Restore Sensitivity HGF Resistance to SOC induced by VEGF/HGF upregulation VEGF mabs VEGF HGF mabs VEGF + MP25 MP25 breaks the resistance to MM drugs HGF 218 Molecular Partners AG Slide 15

16 Oncology MP25 Combination with Velcade Results in Superior Efficacy in Mouse Model MP25 Vehicle Velcade MP25 Velcade + MP25 Bone morphology Muscle invasion by tumor Xenograft model H Molecular Partners AG Slide 16

17 Oncology MP25 Phase 2 Study in MM RRMM Part 1: Dose Escalation Velcade /dexamethasone Part 2: Dose Expansion MP25 8 mg/kg q3wk Velcade /dexamethasone Velcade /dexamethasone MP25 target dose MP25 12 mg/kg q3wk Endpoints: ORR, PFS Total: n 4 MP25 Phase 2 open-label, single-arm, multicenter study of MP25 + Velcade + dexamethasone, patients with refractory and relapsed multiple myeloma (RRMM) Study population: MM patients with 2 lines of therapy, including Velcade + IMiD, (a) without response to most recent therapy or (b) progression within 6 days post most recent treatment Study status*: Cohort 1 completed in H1 18, Cohort 2 ongoing Next readouts: Additional safety and initial efficacy data before end 218 *Data cut-off: 1 April 218 Study details: clinicaltrials.gov/nct Molecular Partners AG Slide 17

18 VGPR PR MR Baseline Oncology MP25 Phase 2 Study in MM Initial Read-out: Promising Signs of Efficacy at initial dose (8mg/kg) MP25 Preliminary results * : Best responses Treatment duration * (5/8 patients with anti-myeloma activity; excludes non-responders) Very good partial response Partial response No response Patient Patient Patient Patient Patient Treatment stopped Treatment Cycle Weeks * Data cut-off: 1 April 218; Initial dose level: 8mg/kg/3weeks. 218 Molecular Partners AG Slide 18

19 Oncology Unique Potential of MP25 in MM Multiple myeloma: 2 nd most common blood cancer MP25 Global market value ~USD 9.8bn, expected to reach > USD 12bn by 221 (7% CAGR) * 75% 25% 1 st /2 nd -line n >1, 1 HGF/ c-met IMiD or PI + mab Transplant PI or IMiD + mab No later-line treatments target these key escape pathways 3 rd /4 th -line n 3, 1 PI IMiD X Y + MP25 MP25: Potential to become backbone for all later lines 1. Including US/5EU/JP. Datamonitor. 218 Molecular Partners AG Slide 19

20 Tumor Volume (mm 3 ) Oncology HGF & VEGF Rationale in NSCLC is Supported by Preclinical & Clinical Data MP Preclinical Rationale MP25 in Lung Cancer Model Treatment (days) Vehicle Tarceva MP25 MP25 + Tarceva HGF Rationale Clinical Rationale Activation of MET pathway appears to be significantly involved in acquired resistance to TKI HGF/c-MET pathway is most frequently observed non-egfr related resistance mechanism to TKI 1 Savolitinib (c-met TKI) + osimertinib (Tagrisso ) produced 28% response in patients who failed Tagrisso and showed MET amplification; c-met amplification (15%) is a subgroup of HGF/c-MET upregulation (6 8%) 2 VEGF Rationale Efficacy of VEGF (anti-angiogenesis) already clinically proven: Avastin studies 3-4 TKI, tyrosine kinase inhibitor. 1. Chabon JJ, et al. Nat Commun 216; 2. Spigel R, et al. J Clin Onc 217; 3. Sandler A, et al. N Engl J Med 26; 4. Reck M, et al. J Clin Oncol Molecular Partners AG Slide 2

21 Oncology Unique Potential of MP25 in EGFR mut NSCLC MP25 Current Treatment Option 1 Treatment Line Current Treatment Option 2 HGF/c-MET Iressa or Tarceva Tagrisso n 35 1 Tagrisso MP25 Tagrisso + Our Phase 2 Study 1 st -line 2 nd -line n rd/ 4 th -line n 15 1 HGF/c-MET MP25 Tagrisso + Our Phase 2 Study NSCLC is leading cause of cancer death Activating EGFR mutations are found in ~4% (Asia), ~2% (US), and ~15% (EU) NSCLC 2 Global market value (EGFR NSCLC) ~USD 2.8bn, expected to reach >3.5bn by 223 (5% CAGR) 3 No targeted drug approved after patients progress under Tagrisso treatment 1. Including actively treated, Stage IIIb and Stage IV prevalent cases in US/5EU/JP. Based on Datamonitor; 2. Tang, et al. Oncotarget 216; 3. Datamonitor 218 Molecular Partners AG Slide 21

22 Oncology MP25 Phase 2 Study in NSCLC MP25 EGFR mut NSCLC after Tagrisso n=6 Part 1: Dose Escalation Tagrisso MP25 8 mg/kg q3wk Tagrisso Part 2: Dose Expansion n=34 Tagrisso MP25 target dose Endpoints: ORR, PFS n=6 MP25 12 mg/kg q3wk Status: FDA approval Sep st oncology DARPin drug candidate in US Collaboration with AstraZeneca for Tagrisso supply 1 st patient to be dosed in the coming weeks Next readouts: initial safety in 218 & initial efficacy 219 *The study details can be found on clinicaltrials.gov/nct Molecular Partners AG Slide 22

23 Oncology MP274: Killing HER2+ Cells with New MoA Medical need: eventually advanced cancer patients progress on standard antibody-based HER2+ treatments MP274 is an allosteric inhibitor of HER2 blocking HER2- and HER3- mediated signaling and inducing apoptosis New mode of action: induction of apoptosis in HER2-addicted cancer cells independent of ADCC compared with approved therapies MoA may help patients not adequately responding to current therapies Ongoing Phase 1 in HER2 positive tumor patients progressing on SOC HSA DARPin HER2 DARPin B MP274 HER2 DARPin A Fully owned by Molecular Partners IP protection until at least Molecular Partners AG Slide 23

24 Oncology MP274 Forces Her2 in Conformational Deadlock Leading to Cell Death MP274 Her2 EC-Domain Trastuzumab & Pertuzumab MP274 Bi-paratopic DARPin Perjeta Herceptin Her2 has several «active sites» with conformational flexibility Herceptin and Perjeta block two distinct Her2 functions MP274 handcuffs Her2 into fully inactive conformation*, acting as broad-range allosteric inhibitor EC: extracellular; *model 218 Molecular Partners AG Slide 24 * model picture

25 Oncology Direct Induction of Tumor Cell Death with MP274 «Open» MP274 «Locked» MP274 HER1 HER2 HER3 Apoptosis Effector-cell independent tumor cell death Natural Killer Cell HER2 signals tumor cell survival & proliferation ADCC Effector-cell mediated tumor cell death Herceptin & Perjeta ADCC, antibody-dependent cellular cytotoxicity. 218 Molecular Partners AG Slide 25

26 % Killing Oncology MP274 is a Highly Potent Tumor Cell Killer 1 8 Tumor Cell Apoptosis BT474 MP Tumor Cell Killing BT474 MP274 Ado-trastuzumab emtansine (Kadcyla ) MP [nm] Trastuzumab/ Pertuzumab (Herceptin / Perjeta ) New MoA may help patients who do not adequately respond to current therapies [nm] 218 Molecular Partners AG Slide 26

27 Tumor Volume (mm 3 ) Relative Tumor Volume (%) Oncology MP274 Efficacy in PDX Mouse Models MP274 Vehicle Trastuzumab Trastuzumab + Pertuzumab MP274 2 Breast cancer PDX model Maca4898 (Her2 IHC2+) 8 Gastric cancer PDX model GXA339 (Her2 IHC3/2+) 1 5 Colorectal cancer PDX model CXF1991 (Her2 IHC3+) Treatment (days) Molecular Partners AG Slide 27

28 Oncology MP274: Phase 1 Study in HER2+ Cancer Patients Phase 1, first-in-human, single-arm, multicenter, open-label, repeated-dose, dose escalation study assess safety, tolerability and pharmacokinetics of MP274 in patients with advanced HER2-positive solid tumors with expansion cohort at recommended dose to confirm safety and to assess preliminary efficacy Primary objective: Assess safety and tolerability of MP274 in heavily pretreated patients with HER2-positive solid tumors who have progressed after standard therapy for advanced disease Study treatment: Dose Escalation (Part A): 4 dose groups Dose Expansion (Part B) at recommended dose: 26 patients (total of up to 32 patients at target dose) Status: First patients dosed; 2 nd patient showed changes in ECG parameters, most likely not associated with MP274 Pharmacological effect of MP274, though very unlikely, could not be completely ruled out Phase 1 enrollment temporarily suspended and additional cohorts to explore lower doses added to protocol Study recruitment expected to continue in Q3 218 Next readouts: Initial safety data expected in Q4 218 and first efficacy data in 219 MP274 *Study details: clinicaltrials.gov/nct Molecular Partners AG Slide 28

29 Improving the Therapeutic Index of IO Agents I/O KILL T-Cell Engagers Immunecell ACTIVATE Costimulatory Targets BLOCK Checkpoint Targets Toxicity Efficacy Tumor Cells Tumor localized IO agents may achieve both, reduce systemic toxicity and improve efficacy 218 Molecular Partners AG Slide 29

30 I/O How do we achieve the improved therapeutic index? IN CIRCULATION (SYSTEMIC) IN CIRCULATION (SYSTEMIC) Clustering: activation of T-cells everywhere in body IN THE TUMOR IN THE TUMOR Activated T-cell Cell Activated T-cell Tumor Cell No Clustering = no effect Tumor Stroma Clustering: T-cell activation Stimulator SWITCH Localizer 218 Molecular Partners AG Slide 3

31 Luminescence Signal Luminescence Signal I/O All Successful DARPin Stimulators to Date , OX-4 4-1BB Link A, et al. EACR 217. Abstr , 3, 2, 1, 5, 4, 3, 2, 1, DARPin Concentration (nm) CD OFF ON OFF Without Clustering With Clustering SWITCH 218 Molecular Partners AG Slide 31

32 DARPin Toolbox with Unlimited Opportunities: MP31 as the «Pilot» Localizer I/O Switch Stimulator A OX-4 4-1BB a CD4 c B FAP MP31 C D Many DARPin candidates are under investigation for both solid and liquid tumors (including combinations) 218 Molecular Partners AG Slide 32

33 I/O MP31: Activating T-cells (only) in the Tumor FAP: 4-1BB Tumor-restricted expression of FAP used to direct T-cell co-stimulation MP31 Tumor-selective activation of T cells No systemic side effects expected Potential to combine with other IO SOCs (anti-pd-1, anti-ctla4) HSA DARPin FAP DARPin Fully owned by Molecular Partners IP protection at least until BB DARPin FAP, fibroblast activation protein. 218 Molecular Partners AG Slide 33

34 Animals (n) M e a n tu m o r v o lu m e [m m 3 ] I/O CD8 T-Cells Overview of MP31 Data MP31 No systemic toxicity Ideal for combinations 1 Body weight loss >1% 2 Vehicle TAA-CD3-AB 4 * * * * * * Control Antibody MP31 1/1 8/1 1/ TAA-CD3-AB + MP H u m a n C D 8 T c e lls *** * * * p e r.2 g tu m o r V e h ic le 3. 5 m g /k g a n ti-t A A /C D 3. 5 m g /k g a n ti-t A A /C D m g /k g a n ti-4-1 B B /F A P D A R P in m o le c u le 1 T re a tm e n t d a y s MP31 shows lower systemic toxicity compared with current therapy Would be ideal combination partner with other drugs ***p<.1, 2-way ANOVA. 218 Molecular Partners AG Slide 34

35 Abicipar Retinal Diseases: Unmet Medical Needs Remain Wet AMD and DME are leading causes of blindness in Western world Large and rapidly growing group driven by aging population Current standard of care is Lucentis or Eylea Both require monthly intravitreal injections Significant unmet medical need for less frequent injections and doctor office visits 218 Molecular Partners AG Slide 35

36 Abicipar Abicipar: Most Advanced DARPin Therapy Abicipar Long-acting PEGylated mono-darpin protein blocking VEGF Potentially transformative therapy with less frequent ocular injections compared with standard of care Phase 2 data suggest quarterly dosing and comparable efficacy to Lucentis Drug Safety Monitoring Committee (DSMC): no changes recommended anti-vegf DARPin Wet AMD Phase 3 one-year data in H2 218; Allergan plans launch in 22 Allergan plans to start DME Phase 3 in H Molecular Partners AG Slide 36

37 BCVA (letters ± SE) Abicipar Phase 2 Data Suggest Quarterly Dosing for Wet AMD Dosing Change of Best-Corrected Visual Acuity (BCVA)* Abicipar 2. mg Abicipar 1. mg Lucentis.5 mg Week Safety Data Vision Gain (letters) Safety (n/n) Wk 16 Wk 2 AEs / / /16 Abicipar The abicipar formulation has been further optimized for safety for use in Phase 3. Allergan, 12 August 214. *Study not powered to reach statistical significance; Ocular inflammation. SE, standard error. 218 Molecular Partners AG Slide 37

38 Abicipar CEDAR & SEQUOIA: Abicipar Registration Studies in wet AMD Abicipar 2 mg q12w Abicipar 2 mg q8w Lucentis.5 mg q4w Loading Doses Primary Endpoint Extension Week Abicipar 2 parallel, randomized, double-blind phase 3 studies 2x 9 patients globally Patient recruitment completed since early May 217 (4 months ahead of plan) Drug Safety Monitoring Committee (DSMC): no changes recommended Next milestones: 1 year topline read-out in 218 (triggers FDA filing), targeted launch in Molecular Partners AG Slide 38

39 CAGR: 18% Abicipar Opportunities in the Wet AMD and DME Market Global Wet AMD and DME Market Size (USDbn) 1 * Abicipar Other USD 8bn annual sales (216) and growing (wet AMD and DME) SOC: Eylea and Lucentis : bi-monthly or monthly injections Aflibercept (Eylea ) Ranibizumab (Lucentis ) Global license agreement with Allergan all development costs borne by Allergan Up to $36mn open milestones & low double-digit to mid-teen tiered royalties Reported by EvaluatePharma, a service of Evaluate Ltd. (UK), Accessed 27 Apr 215. *Avastin is used off label. 218 Molecular Partners AG Slide 39

40 Multiple Value Inflection Points Ahead Abicipar wamd: 1-y Ph 3 efficacy DME: Ph 3 expected start wamd: expected launch in 22 MP25 MM: initial efficacy NSCLC: initial safety MM: efficacy NSCLC: initial efficacy NSCLC: efficacy MP274 Initial safety Initial efficacy MP31 Preclinical data FIH Funding into Molecular Partners AG Slide 4

41 Investment Case and Key Messages Successful transition from DARPin platform into clinical product company Key value inflection points ahead: MP25 (2x Phase 2) and MP274 (Phase 1) in oncology Abicipar (Phase 3 data) in ophthalmology MP31 selected as 1 st development candidate from our I/O DARPin toolbox Financed into 22, capturing key value inflection points Keep on forward integrating towards late-stage development and the market DARPin is a registered trademark owned by Molecular Partners AG. 218 Molecular Partners AG Slide 41

42 Appendix 218 Molecular Partners AG Slide 42

43 Appendix Experienced Management Team Dr. Patrick Amstutz, CEO Co-founder, former CBO & COO PhD in molecular biology from UZH Dr. Andreas Harstrick, CMO, MD 3 years of experience in oncology, including Erbitux development Brought four mab oncology products to market Senior executive roles at Merck-Serono, Imclone, Eli Lilly Dr. Michael Stumpp, CSO Co-founder PhD and postdoc from UZH; research in Tokyo, London Andreas Emmenegger, CFO Joined 27 as CFO and first investor Former CFO Glycart and Head Strategic Alliance Genentech at Roche >2 years experience as CFO of private & listed companies; raised >$.5bn, including two IPOs 218 Molecular Partners AG Slide 43

44 Appendix Experienced and Independent Board of Directors Bill Burns, Chairman Former CEO of Roche Pharmaceuticals Former board member of Roche, Genentech, Chugai Pharmaceuticals Göran Ando, Vice Chairman Former Chairman, Novo Nordisk Former CSO, Pharmacia Steven H. Holtzman President and CEO, Decibel Therapeutics Former EVP, Biogen William Bill Lee EVP Research, Gilead Gwen Fyfe Former VP, Oncology Development at Genentech Petri Vainio Managing Director, Essex Woodlands Ventures Patrick Amstutz Co-founder, CEO Molecular Partners 218 Molecular Partners AG Slide 44

45 Appendix Financial Summary FY 17 (CHF million; as per IFRS) FY 217 FY 216 change Revenues (3.) Total expenses 1 (45.8) (42.5) (3.3) Operating result EBIT (25.8) (19.5) (6.3) Net financial result.4.9 (.5) Net result (25.4) (18.6) (6.8) Net cash from (used in) operations (4.) (35.4) (4.6) Cash balance (39.1) Financial Guidance for Full-Year Total expenses of ca. CHF 5-6 million, of which ca. CHF 5 million non-cash effective costs Capital expenditures of ca. CHF 3 million on top No guidance on net cash flow; timelines and potential milestone payments with partnerships not disclosed Guidance subject to progress and changes in pipeline 1 Thereof non-cash costs of CHF 4.9m in FY217 and CHF 4.7m in FY Including CHF 9.8 million short-term time deposits 3 Including CHF 3.5 million short-term time deposits 4 Financial guidance issued with FY 217 Results release on February 8, Molecular Partners AG Slide 45

46 Appendix Shareholder Structure Shareholder structure as of Dec 31, 217 Highlights VC holdings reduced to 23% (from 42% end of 216) 23% Listed on SIX Swiss Exchange (SIX: MOLN) 59% Included in key indices: SPI, SPI Extra, SXI Life Sciences and SXI Bio+Medtech 18% 21,44,62 shares outstanding as of December 31, 217 CHF 553 million market cap. as of December 31, 217 No lock-up restrictions in place Pre-IPO investors (4 VC's) Management, Board, Founders Others Formal free float as per SIX definition: 77% 218 Molecular Partners AG Slide 46

47 Mean Change in BCVA (letters ± SE) Phase 2 Data Showing Long Duration of Action in DME Appendix Abicipar Primary Loading Doses Endpoint Vision gain (letters) Safety Week Abicipar 2 mg q12w Abicipar 2 mg q8w Abicipar 1 mg q8w Lucentis.5 mg q4w Wk 28 AEs (n/n) 7.2 4/ / / / Lucentis.5 mg q4w Abicipar 2 mg q12w Week The abicipar formulation has been further optimized for safety for use in Phase Molecular Partners AG Slide 47

48 Abicipar Abicipar: Part of Allergan s key pipeline highlights Abicipar Source: Allergan Q1 218 Presentation (April 3, 218). Source: Allergan Presentation at Leerink Partner conference (Feb 15, 217). 218 Molecular Partners AG Slide 48

49 Appendix IR Agenda Date Event August 3, 218 Publication of Half-year Results 218 November 1, 218 Q3 218 Management Statement 218 Molecular Partners AG Slide 49

50 Appendix Disclaimer This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a recommendation regarding the shares. This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like potential, believe, assume, expect, forecast, project, may, could, might, will or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Molecular Partners AG and investments and those explicitly or implicitly presumed in these statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Molecular Partners AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Molecular Partners AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements. Unless stated otherwise the information provided in this presentation are based on company information. This presentation is intended to provide a general overview of Molecular Partners AG s business and does not purport to deal with all aspects and details regarding Molecular Partners AG. Accordingly, neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith. The material contained in this presentation reflects current legislation and the business and financial affairs of Molecular Partners AG which are subject to change and audit. 218 Molecular Partners AG Slide 5

51 Molecular Partners AG Wagistrasse Zürich-Schlieren Switzerland T Molecular Partners AG Slide 51